← board
PRTA
distress 1/10 · well-funded / low risk$8.32-1%today-28% from 52w high
Lead: ATTR amyloidosis with cardiomyopathy
Revenue
$51M
Liquidity
$329M
Runway
4.0 yrs
Shares 1y
-3%
Price & events
-19.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-1.8%
1W
-12.9%
1M
-22.5%
3M
-16.8%
6M
+23.1%
1Y
-65.8%
2Y
-84.0%
5Y
-32.4%
All
Overview
- Market Cap
- $435.58M
- Volume
- 39.99K
- 52 Week Range
- $6.22 – $11.51
- Total Shares
- 52.35M
- Float Shares
- 36.68M
- Short %
- 19.18%
- % Held by Insiders
- 20.18%
- % Held by Institutions
- 90.76%
- RVOL
- 0.07x
- Beta
- -0.31
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 8
- 2026Guided 40%conferencedata presentationsecondaryProgram updates from Bristol Myers SquibbSEC 8-K
- 2026-08-03Estimated 45%earningsEarningsEarnings releaseyahoo
- 2H25conferencedata presentationsecondaryProgram updates from Novo NordiskSEC 8-K
- in 2025trial initiationsecondaryPhase 3coramitug · Novo Nordisk expects to initiate Phase 3 program for coramitug in ATTR-CM in 2025.SEC 8-K
- August 2025readoutPhase 1PRX012 · Initial data from Phase 1 ASCENT clinical trialsSEC 8-K
- 2025-08-06partnershipcoramitug · Novo Nordisk decided to advance coramitug into Phase 3 development after successful Phase 2.SEC 8-K
- mid-year 2025conferencedata presentationsecondaryProgram updates from RocheSEC 8-K
- 2025-05-23trial discontinuedbirtamimab · Development discontinued including open label extensionSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-08CitizensMarket Outperform
- 2026-02-20RBC CapitalSector Perform
- 2025-12-01CitizensMarket Outperform
- 2025-11-07HC Wainwright & Co.Buy
- 2025-11-07RBC CapitalSector Perform
- 2025-10-28Piper SandlerOverweight
Competitors — ATTR amyloidosis with cardiomyopathy
- NTLAIntellia Therapeutics, Inc.$1.5B · D7
Recent news
- 2026-07-20Trading the Move, Not the Narrative: (PRTA) Edition - Stock Traders Daily
- 2026-07-14PRTA Q1 2026 Earnings: Strong EPS Beat Driven by Non-Operating Income, Stock Dips Despite Surprise - Guidance Downgrade Alert - dars.gov.et
- 2026-07-14PRTA Q1 2026 Earnings: Strong EPS Beat Driven by Non-Operating Income, Stock Dips Despite Surprise - Earnings Call Highlights - dars.gov.et
- 2026-07-13Prothena (PRTA) Price Target Increased by 37.50% to 16.83 - MSN
- 2026-07-10PRTA Q1 2026 Earnings: Surprise Profit Beats Estimates Amid Pre-Revenue Status, Stock Declines 4.15% - Earnings Yield Spread - dars.gov.et
- 2026-07-09Trading the Move, Not the Narrative: (PRTA) Edition - Stock Traders Daily
- 2026-07-09PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? - Yahoo Finance
- 2026-07-05Prothena (PRTA) Posts Fractional Gain as Biotech Sector Wobbles - TPO Profile - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.